Exelixis Announces Preliminary Fiscal Year 2023 Financial Results, Provides 2024 Financial Guidance, and Outlines Key Priorities and Milestones for 2024 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
- Total Revenues of $471.9 million, Cabozantinib Franchise U.S. Net Product Revenues of $426.5 million Conference Call and Webcast Today at 5:00 PM Eastern Time -ALAMEDA, Calif. (BUSINESS WIRE) Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the third quarter of 2023 and provided an update on.
Operator: Good day, ladies and gentlemen, and welcome to the Exelixis Secod Quarter 2023 Financial Results Conference Call. My name is Tawanda and I ll be your operator for today.